Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models

Fig. 4

Clinical efficacy predicted for both 6 month periods and cumulative predicted clinical efficacy in time. Predicted estimates of clinical efficacy at each 6 month follow-up, and cumulatively in time for the EPI and 5–17 month cohort over all trial sites. Reported efficacy at 18 months post third dose (mean and 95 % CI) over all trial sites for each cohort is indicated by red. Prediction estimates by 6 month time periods (mean) are shown in blue bars for each cohort, 5–17 months (left) and EPI (right). Predictions for cumulative efficacy in time are shown in black, with purple shading to indicate difference between 6 month period predictions. Predictions are from the best fitted model (fit to both cohorts, fit half-life, and site-specific variation), with the adjusted transmission assumptions (ii)

Back to article page
\